ArticleThe American journal of case reports2025
Unpredictable Evolution of Pilocytic Astrocytoma in Adults: A Case Series and Diagnostic Challenges.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Pilocytic astrocytomas are WHO grade 1 tumors frequently identified in children and young adults, with a male predominance. This pathology is uncommon in adults, representing 0.8% of central nervous system tumors. The significance of these tumors is underscored by their recurrence rates, which are 38.9% following subtotal resection and 4% after complete resection. This study presents 4 cases of female patients, aged between 58 and 76 years, managed in our service in the last 15 years. CASE REPORT Clinical manifestations (headache, nausea, and vomiting) were nonspecific. Imaging helped in 1 case. In 3 cases, imaging caused confusion by indicating either a stroke (1 case) or metastases (2 cases). Diagnosis was determined through histopathological examination. Immunohistochemical assays were conducted to confirm the diagnosis (IDH1, Ki-67, Nestin, and p53) and to evaluate the prognosis and risk of progression/recurrence of the cases (MGMT and PTEN). Of the 4 cases, there was 1 case of tumor progression and 1 of death. Two cases presented a favorable evolution, surviving without disabilities 5 years after diagnosis. We compared our results with other studies and observed similarities and differences between patients, including variations in age and sex. CONCLUSIONS This rare tumor's nonspecific symptomatology and imaging make diagnosis and prognosis difficult. The cases illustrate the significant role of immunohistochemical assays in diagnosing and evaluating patient prognosis. The clinical applicability of these tests must be corroborated with clinical presentation and neurosurgical resection to highlight progression and recurrence rates. Standardized protocols and molecular-based evidence are essential for optimizing patient management and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.